医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Takeda Acquires U.S. Biologics Manufacturing Facility

2016年01月06日 AM08:00
このエントリーをはてなブックマークに追加


 

OSAKA, Japan

Takeda Pharmaceutical Company Limited (TOKYO:4502) (“Takeda”) today announced the acquisition of a biologics manufacturing facility located in Brooklyn Park, Minnesota, U.S., from Baxalta US Inc (NYSE:BXLT). Takeda intends to use the facility primarily for the manufacture of Entyvio® (vedolizumab) and other biologic products, allowing the company to maximize global efficiencies and further enhance the product’s supply chain flexibility.

“Takeda’s focus is providing patients access to quality therapies,” said Thomas Wozniewski, Global Manufacturing and Supply Officer at Takeda. “Acquiring the state of the art Brooklyn Park facility and gaining access to a highly experienced and dedicated team is a very important strategic benefit for Takeda that reinforces and expands upon our global operations for Entyvio and future biologic products.”

The acquisition will also provide long-term strategic benefits for Takeda through enhanced capacities for the manufacture of additional commercial products and investigational drugs under clinical development. The plant allows Takeda to establish and develop direct commercial bio-manufacturing expertise. Terms of the transaction were not disclosed.

About Takeda Pharmaceutical Company Limited
Located in Osaka, Japan, Takeda (TOKYO:4502) is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for people worldwide through leading innovation in medicine. Additional information about Takeda is available through its corporate website, www.takeda.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160105005639/en/

CONTACT

Media Contacts:
Japanese Media
Tsuyoshi Tada,
+81 (0)3-3278-2417
tsuyoshi.tada@takeda.com
or
Media
outside Japan

Jocelyn Gerst, +1 (224) 554-5542
jocelyn.gerst@takeda.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Dompé用于治疗中度或重度神经营养性角膜炎成人患者的Oxervate®(Cenegermin滴眼液)获得欧盟CHMP肯定意见
  • SCIEX Sponsored Award Recognizes Notable Contributions to Electrodriven Separations
  • LMDのV-Sensorがインドでバイタルサインを測定
  • オクタファルマ、薬物動態に基づくNuwiq®個別化予防療法(NuPreviq法)に関する新しい臨床データの発表により、血友病A患者への強いコミットメントを浮き彫りに
  • ハーバライフ・ニュートリション、健康的でアクティブな生活を促すリーダーとなれるよう、東南アジアのメンバーを鼓舞